advertisement
Abstract #21623 Published in IGR 10-3
Follow-up study for immediate argon laser peripheral iridoplasty as the treatment for acute attack of primary angle-closure glaucoma
Chen P; Zhao K-HInternational Journal of Ophthalmology 2008; 8: 1464-1466
AIM: To study the efficacy, safety and persistency of argon laser peripheral iridoplasty (ALPI) as a first-line treatment for acute primary angle-closure glaucoma (PACG). METHODS: Twenty-three cases (23 eyes) with acute PACG were recruited into the study. Each of them received topical pilocarpine (1%), timolol (0.5%), and immediate ALPI as primary treatment. The intraocular pressure (IOP) of 2 hours, 1, 3, 6, 9 and 12 months after surgery were documented. The angle of anterior chamber was observed at each follow-up time. Dark room and prone provocative tests were done at 1, 3, 6, 9 and 12 months after surgery. RESULTS: The mean IOP of 23 eyes was reduced from 69.43 ± 8.22 mmHg, before ALPI, to 15.74 ± 3.09 mmHg at 2 hours after surgery. All eyes did not have ocular hypertension during the follow-up time. Compared with the closure of anterior chamber angle before ALPI, it was widened after surgery under goniscope and the trabecular meshwork was visualized widely in static state. The results of dark room and prone provocative tests were negative at 1, 3, 6, 9 and 12 months after surgery. CONCLUSION: Argon laser peripheral iridoplasty, without adjunctive systemic carbonic anhydrase inhibitors and hyperosmotic agents, appears to be effective and safe in controlling the IOP in acute PACG, efficacy is persistent during the follow-up time. LA: Chinese
Dr. P. Chen, Department of Ophthalmology, Beijing Shijingshan Hospital, Beijing 100043, China. chenping1801@tom.com
Classification:
9.3.1 Acute primary angle closure glaucoma (pupillary block) (Part of: 9 Clinical forms of glaucomas > 9.3 Primary angle closure glaucomas)
12.3 Laser iridoplasty (Part of: 12 Surgical treatment)
